BONESUPPORTs annual report for 2018 is now available as a pdf on the group’s web page, www.bonesupport.com. A PDF-version is also attached to this press release.
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46(0) 46 286 53 70
+46 (0)708 76 87 87
This information is such that BONESUPPORT is obliged to make public pursuant to the Swedish Securities Market Act (2007: 528) (VpmL). The information was submitted for publication, through the agency of the contact person set out below, on 17 April, at 18:00 CET.